- Patent Title: Immunological biomarker for predicting clinical effect of cancer
-
Application No.: US16484071Application Date: 2018-02-06
-
Publication No.: US11293924B2Publication Date: 2022-04-05
- Inventor: Hiroshi Kagamu
- Applicant: Saitama Medical University
- Applicant Address: JP Saitama
- Assignee: Saitama Medical University
- Current Assignee: Saitama Medical University
- Current Assignee Address: JP Saitama
- Agency: Seed IP Law Group LLP
- Priority: JPJP2017-020685 20170207,JPJP2017-110069 20170602
- International Application: PCT/JP2018/004090 WO 20180206
- International Announcement: WO2018/147291 WO 20180816
- Main IPC: G01N33/574
- IPC: G01N33/574 ; C07K16/18 ; C07K16/28

Abstract:
The present invention relates to the prediction of responsiveness to cancer immunotherapy of a subject based on the T-cell composition of the subject, and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining responsiveness to cancer immunotherapy of a subject. Responsiveness to cancer immunotherapy is predict by determining a relative value of a CD4+ T-cell subpopulation, dendritic cell subpopulation, and/or CD8+ T-cell subpopulation correlated with a dendritic cell stimulation in an anti-tumor immune response in a sample derived from a subject. A composition for treating or preventing cancer comprising cells such as CD62LlowCD4+ T-cells is also provided.
Public/Granted literature
- US20200025768A1 IMMUNOLOGICAL BIOMARKER FOR PREDICTING CLINICAL EFFECT OF CANCER Public/Granted day:2020-01-23
Information query
IPC分类: